Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
申请人:Wyeth
公开号:US20040167122A1
公开(公告)日:2004-08-26
The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
1
本发明提供了一种I式化合物及其在治疗与5-HT6受体相关或受其影响的疾病中的应用。
5-Piperazinyl-3-sulfonylindazoles as Potent and Selective 5-Hydroxytryptamine-6 Antagonists
作者:Kevin G. Liu、Albert J. Robichaud、Ronald C. Bernotas、Yinfa Yan、Jennifer R. Lo、Mei-Yi Zhang、Zoe A. Hughes、Christine Huselton、Guo Ming Zhang、Jean Y. Zhang、Dianne M. Kowal、Deborah L. Smith、Lee E. Schechter、Thomas A. Comery
DOI:10.1021/jm1007825
日期:2010.11.11
Herein we report the identification of a novel series of 5-piperazinyl-3-sulfonylindazoles as potent and selective 5-HT6 antagonists. The synthesis, SAR, and pharmacokinetic and pharmacological activities of some of the compounds including 3-(naphthalen-1-ylsulfonyl)-5-(piperazin-1-yl)-1H-indazole (WAY-255315 or SAM-315) will be described.
HETEROCYCLYL-3-SULFONYLINDAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
申请人:Bernotas Ronald Charles
公开号:US20090253711A1
公开(公告)日:2009-10-08
The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor.
本发明提供了一种I式化合物及其在治疗与或受5-HT6受体相关的疾病中的应用。
Heterocyclic derived metalloprotease inhibitors
申请人:Janssen Pharmaceutica NV
公开号:US07803793B2
公开(公告)日:2010-09-28
This invention provides novel heterocyclic derived matrix metalloprotease inhibitors of the formula:
and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing matrix metalloproteases. This invention also provides therapeutic and prophylactic methods using the instant pharmaceutical compositions.
Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs)
作者:Yue-Mei Zhang、Xiaodong Fan、Shyh-Ming Yang、Robert H. Scannevin、Sharon L. Burke、Kenneth J. Rhodes、Paul F. Jackson
DOI:10.1016/j.bmcl.2007.10.049
日期:2008.1
Several classes of arylsulfone-based MMP-2/-9 inhibitors utilizing 6- to 8-membered heterocyclic rings as zinc-binding groups (ZBGs) have been synthesized and their enzyme inhibitory activities were evaluated. Although a number of 6- and 7-membered heterocycles were effective, the most potent arylsulfone inhibitors are based on the rigid 1- or 3-hydroxypyridone ZBG. (C) 2007 Elsevier Ltd. All rights reserved.